Adverum Biotechnologies. has been granted a patent for modified adeno-associated virus (AAV) virions that enhance retinal cell infectivity and alter tropism. The invention includes methods for gene delivery and treatment of ocular diseases, featuring a polynucleotide encoding a modified AAV capsid protein with heparan sulfate binding capabilities. GlobalData’s report on Adverum Biotechnologies gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Adverum Biotechnologies, Adeno-associated virus vectors was a key innovation area identified from patents. Adverum Biotechnologies's grant share as of July 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
Modified aav capsid for enhanced retinal cell targeting
The granted patent US12030914B2 outlines a polynucleotide that encodes a modified adeno-associated virus (AAV) capsid protein, specifically AAV2.5T/7m8, which includes one or more amino acid modifications that enhance heparan sulfate binding. The claims detail various specific modifications, including point mutations such as S576R and T579R, as well as substitutions of amino acid residues within defined ranges. The patent also specifies different variants of the AAV2.5T/7m8 capsid, including AAV2.5T/7m8(+3), AAV2.5T/7m8(0), AAV2.5T/7m8(-12), and AAV2.5T/7m8(-3), indicating a focus on optimizing the capsid's properties for potential therapeutic applications.
Additionally, the patent encompasses the creation of expression vectors containing the polynucleotide, which can be linked to a promoter sequence for effective expression in host cells. The claims extend to cells that incorporate these expression vectors, including those that may also encode therapeutic proteins or rep proteins. Notably, the patent identifies specific cell types, such as HEK293, SF-9, A549, or HeLa cells, as suitable for maintaining the modified capsid protein and rep protein. Furthermore, a method for producing the modified AAV capsid protein through the expression of the polynucleotide in a cell is also described, highlighting the potential for developing advanced gene therapy vectors.
To know more about GlobalData’s detailed insights on Adverum Biotechnologies, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
